Multiple Myeloma Treatment Advances Promote a Future of Individualized Patient Care
Jeffrey V. Matous, MD, highlights takeaways from the phase 3 IKEMA trial and notes the benefits of administering CAR T-cell therapy in earlier lines, as evidenced in primary results from the phase 3 CARTITUDE-4 trial.
Source: onclive.com